Noah Medical

1.1 Identity, mission, and the Galaxy product

Noah Medical is a privately held medical-robotics company based in San Carlos, California, in Silicon Valley, with its headquarters address (1501 Industrial Rd) independently confirmed on the FDA 510(k) record for its lead product. Private databases place the company's founding around 2018, though Noah Medical does not publicly confirm an exact incorporation date. The company's stated mission is to deliver adoptable clinical solutions through innovative endoluminal technologies that enhance the quality of life for patients globally, framed concretely around earlier, more accurate lung-cancer diagnosis. Its first and only commercial product is the Galaxy System, a robotic-assisted (navigated) bronchoscopy platform intended to provide bronchoscopic visualization of, and access to, patient airways for diagnostic and therapeutic procedures. The Galaxy System combines proprietary TiLT+ Technology with integrated digital tomosynthesis and augmented fluoroscopy, an always-on single-use disposable bronchoscope, and a compact footprint; the company markets it as the only navigated bronchoscopy system with a single-use scope and as its inaugural commercial robotic system. The business model centers on selling the Galaxy capital system plus single-use disposables for peripheral lung-nodule biopsy.[CO001, CO003, CO004, CO005, CO006, CO007]

1.2 Founder, leadership team, and governance visibility

Noah Medical is led by founder and CEO Jian Zhang, a surgical-robotics entrepreneur whose founder-market fit is unusually strong: he was employee #2 at Auris Health, acquired by Johnson & Johnson for $5.7 billion in 2019, previously worked at Intuitive Surgical, holds MS and PhD degrees from Columbia University, and co-founded prior startups including Robotphoenix. The public leadership page lists a functional executive bench drawn heavily from Intuitive, Auris, Stryker, Verb Surgical, and other top robotics companies, including Ivy Li as Interim CFO, Joe Riley as VP of Sales and Marketing, John Shen as VP of Engineering, Nicky Espinosa as General Counsel, John Mesenbring as VP of Manufacturing Operations, and Brent Lloyd as VP of Service and Technology Operations. In June 2026 the company appointed Dr. Krish Bhadra, a Stanford Medicine interventional pulmonologist who has performed more than 2,300 robotic-assisted bronchoscopy procedures, as Chief Pulmonary Advisor in a newly created role. The most material governance gap is that the board of directors, investor board seats, and ownership structure are not publicly disclosed, and the CFO role is still held on an interim basis, both of which are key-person and governance considerations for diligence.[CO002, CO011, CO012, CO013, CO014, CO015]

1.3 Funding history, investors, and capital structure

Noah Medical's clearest financing anchor is an oversubscribed $150 million Series B round announced on April 19, 2023, led by the SoftBank Vision Fund and co-led by Prosperity7 Ventures, a venture subsidiary affiliated with Saudi Aramco. The syndicate also included Tiger Global and existing investors Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, and AME Cloud Ventures, alongside undisclosed strategic investors. Independent deal coverage corroborates the round size, lead investors, and syndicate composition. Beyond the Series B, the company's total capital raised is not fully disclosed; third-party databases indicate more than $150 million raised as of 2023, implying earlier seed and Series A activity that Noah Medical has not detailed publicly. Critically, Noah Medical has not disclosed a post-Series-B valuation, current cap table, liquidation preferences, or board-level investor rights. That combination of a marquee investor base and limited structural disclosure means the capital story is strong on demand signals but thin on the control and economics detail an investor would need to underwrite ownership and downside protection.[CO019, CO020, CO021, CO022, CO023, CO024]

1.4 Milestones, commercial traction, and clinical evidence

Noah Medical's milestone arc is coherent and well-documented. After announcing new research, testing, and training facilities in March 2022, the company received FDA 510(k) clearance (K223144) for the Galaxy System on March 1, 2023, as a substantially equivalent Class II device. It then completed first-in-human use in the FRONTIER study at Macquarie University Hospital in Sydney under Principal Investigator Professor Alvin Ing (March 2023), closed its Series B (April 2023), and performed the first U.S. commercial cases at the University of Chicago Medicine with Dr. Kyle Hogarth in May 2023, where all four initial patients were discharged the same day. International expansion followed with the first Asian use at Prince of Wales Hospital in Hong Kong (December 2023). Adoption then accelerated from the 500th U.S. procedure at CHI Memorial (January 2024) to surpassing 5,000 U.S. procedures at Long Island Jewish Medical Center (March 2025). Clinical evidence deepened at CHEST 2025, where the MATCH 2 study (31 patients) reported 96.7% strict diagnostic yield and the community-hospital Beyond the Scope study reported 89% yield; MATCH 2 was subsequently published in the peer-reviewed journal Respiratory Medicine in March 2026. The earlier MATCH study had reported 100% navigation and diagnostic yield with 95% tool-in-lesion accuracy.[CO025, CO026, CO027, CO028, CO029, CO030]

1.5 Snapshot metrics, competitive context, and disclosure gaps

As a private company, Noah Medical leaves several cover metrics unsupported by public evidence, and this chapter records them as explicit gaps rather than estimates. Valuation, revenue, customer/account counts, and run-date headcount are all undisclosed; the only headcount signal is an unverified third-party database estimate in the low-300s for early 2026. The competitive context is also a genuine risk to the identity story: robotic-assisted bronchoscopy is described by incumbents as a small but fast-growing segment, and Noah Medical competes against established platforms with larger installed bases, namely Intuitive Surgical's Ion and Johnson & Johnson's Monarch, the latter the first system to market and upgraded with AI-powered MONARCH QUEST navigation cleared in March 2025. Adoption still depends on hospital capital purchases and procedure economics, a friction every entrant faces. Finally, some of the earliest physician endorsements carry disclosed conflicts of interest: University of Chicago disclosure notes that Dr. Hogarth has been a paid Noah Medical consultant since 2018 and holds an equity interest, which is relevant when weighting early adopter enthusiasm. These gaps are not thesis-breaking, but they define the precise questions later diligence must pursue.[CO023, CO042, CO043, CO044, CO045, CO046]

1.6 Exhibits

2.1 Market Boundary, Substitutes, and Adjacencies

The target market is defined as robotic and navigational bronchoscopy for the evaluation and tissue sampling of pulmonary nodules and early-stage lung cancer, encompassing the hardware platforms (robotic endoluminal systems), single-use disposable bronchoscope catheters, intra-procedural imaging add-ons (mobile cone-beam CT, advanced fluoroscopy), biopsy tool consumables, and the procedure-level software that enables shape-sensing navigation. This scope intentionally excludes standalone CT scanner capital equipment used for primary screening, conventional flexible bronchoscopy without navigational guidance, surgical thoracoscopic/VATS biopsy, radiation therapy devices, and downstream molecular or liquid biopsy testing. Adjacent spend that is not included but materially affects adoption includes hospital EMR/PACS integration middleware, interventional pulmonology suite renovation, and mediastinal staging tools (EBUS-TBNA) that are frequently co-billed. The status-quo substitutes competing directly for the same diagnostic indication are CT-guided transthoracic needle biopsy (CTTB)—the dominant incumbent for peripheral nodules with published yield of 66–100% but pneumothorax rates of up to 25%—and electromagnetic navigation bronchoscopy (ENB, primarily Medtronic's SuperDimension). Conventional flexible bronchoscopy remains the standard for central airway lesions and is largely non-competitive in the peripheral nodule segment. Surgical wedge biopsy provides definitive tissue but with substantially higher morbidity, cost, and inpatient bed consumption. Understanding which spend is included matters critically for sizing: analyst reports that bundle ENB, EBUS, and diagnostic accessories into a broad "interventional pulmonology devices" TAM arrive at figures ten times larger than those that count only purpose-built robotic bronchoscopy platforms.[CM009, CM010, CM011, CM022, CM023, CM024]

2.2 Epidemiological Demand Foundation

The demand signal for pulmonary nodule diagnostics is driven by two converging forces: the burden of lung cancer and the expanding but substantially under-utilized LDCT screening infrastructure. Lung cancer remains the leading cause of cancer death in the United States, accounting for an estimated 229,410 new cases and 124,990 deaths in 2026, representing 20% of all US cancer mortality. The five-year relative survival rate is 29.5%—a persistently poor outcome largely attributable to late-stage diagnosis, since early-stage detection carries survival rates exceeding 60%. The broader determinant of downstream procedural volume is pulmonary nodule detection: approximately 1.6 million nodules are identified annually through chest CT imaging in the United States, detected incidentally in roughly 30% of all chest CTs ordered for other indications. This incidental detection rate has accelerated with the proliferation of CT use for pulmonary embolism, cardiovascular assessment, and trauma, creating a growing backlog of nodules requiring risk stratification and, in a subset, tissue sampling. Against this demand backdrop, the 2021 USPSTF guideline expansion—reducing the eligibility threshold from age 55–80 and 30 pack-years to age 50–80 and 20 pack-years—almost doubled the eligible screening population to approximately 14.1 million US adults. Despite this, only about 18% of those eligible are currently being screened, representing a substantial structural gap. This low uptake is attributed to limited provider awareness, patient stigma around tobacco use, fragmented referral pathways, and lack of shared decision-making capacity in primary care. The implication for the robotic bronchoscopy market is dual: the screening gap constrains the pipeline of CT-detected nodules that would ordinarily funnel into diagnostic biopsy, but it also represents an enormous latent demand pool whose activation—through improved screening programs, AI-driven nodule tracking, and patient navigation—would materially expand the addressable procedure volume.[CM001, CM002, CM003, CM012, CM013, CM014]

2.3 Market Sizing—Multiple Lenses and Contradictions

Market sizing for robotic bronchoscopy is materially contested across analyst sources, with 2025–2026 estimates ranging from $77 million to $640 million for what are nominally described as the same market. Three distinct scope assumptions account for most of this variance. The narrowest definition (Statifacts, 2026: $94.5M) counts only purpose-built robotic catheter systems and their single-use accessories, excluding ENB platforms, EBUS capital, and software subscriptions. An intermediate view (Market Research Intellect, 2026: $640M) bundles robotic systems, accessories, and related software under an "enterprise robotic bronchoscopy" umbrella that includes some navigational and guidance revenue. The broadest perspective (PW Consulting, 2025: $515M, 2026: $609M) aggregates robotic bronchoscopy across all application types and regional geographies under a consistent hospital-procedure unit-economics model. None of these reports publishes its methodology in publicly accessible form, and the CAGR estimates are equally divergent: 5.5% (Data Insights), 18.3% (PW Consulting), and 21.85% (Statifacts) for the same nominal segment over comparable forecast windows. The encompassing interventional pulmonology market provides a more stable anchor: MarkWide Research places the 2026 global total at $4.8 billion growing at 8.7% CAGR through 2036, while ResearchNester sizes 2026 at $4.6 billion at 5.7% CAGR through 2035. North America accounts for 21–38% of global interventional pulmonology volume depending on scope. Constructing a bottom-up US estimate: assuming 500,000 bronchoscopies annually in the US (NLM cited by ResearchNester), robotic platform penetration of approximately 10–15%, average revenue per robotic procedure (equipment + consumables) of roughly $1,500–2,000, yields a US procedure-side SAM of approximately $75–150 million annually—consistent with the narrow Statifacts estimate but far below the enterprise-bundle figures. Investors and analysts relying on the broad estimates without adjusting for scope risk overstating the immediately addressable market for a single-platform company like Noah Medical by a factor of five to eight.[CM004, CM005, CM006, CM007, CM008, CM018]

2.4 Buyer and Payer Segmentation

The hospital is the dominant buyer and operator of robotic bronchoscopy systems. PW Consulting estimates that hospitals account for 79.6% of end-user market share in 2025, with ambulatory surgical centers and diagnostic laboratories representing the remainder. Within the hospital segment, academic medical centers and large tertiary referral hospitals are the clear first movers. Their higher case complexity, access to grant funding, availability of interventional pulmonology fellows, and tolerance for unproven technology economics create conditions favorable to early capital commitment. Community hospitals—which serve the majority of patients with lung nodules in the United States but typically lack fellowship-trained interventional pulmonologists—face a different calculus. Capital budgets at these institutions are constrained, and the $1–2 million upfront system cost represents a multi-year payback at realistic procedure volumes. The emerging model described in MedCity News (March 2026) is the pivot to the endoscopy suite: moving robotic bronchoscopy out of the operating room and into lower-cost outpatient settings while leveraging APC complexity adjustments (CPT 31628 + 31629 + 31653 bundling) to generate contribution margins sufficient to justify the capital. The payer landscape is primarily Medicare for this patient population—lung nodule evaluation skews heavily toward patients over 60 who are Medicare beneficiaries. The relevant reimbursement code is CPT 31627 (navigational bronchoscopy), which pays only $85 at the facility rate in Q2 2026. However, the procedure is typically billed as a bundle with CPT 31628 (bronchoscopy with biopsy) under APC 5153, which generates a higher aggregate payment of roughly $1,800–2,400 per encounter. Commercial payer policies for robotic navigation vary significantly, with some requiring prior authorization, creating administrative friction that disproportionately affects community programs. The budget decision authority sits with hospital CFOs and service-line directors for capital; interventional pulmonologists drive the clinical purchase recommendation. This bifurcated decision structure means sales cycles are long and require both clinical and administrative champions.[CM025, CM026, CM027, CM028, CM029, CM030]

2.5 Growth Drivers and Adoption Constraints

The structural growth thesis for robotic bronchoscopy rests on four reinforcing drivers. First, the USPSTF guideline expansion in 2021—which nearly doubled the eligible screening population to 14.1 million—is progressively increasing LDCT scan volume and therefore the pipeline of detected nodules requiring evaluation. Second, clinical evidence is strengthening: the DYSTRICT study (ERJO, 2025, PMC) demonstrated that shape-sensing robotic bronchoscopy achieved comparable strict diagnostic yield to CT-guided biopsy (74% vs 79%, p=0.201) while delivering substantially lower pneumothorax rates (OR 0.04) and hospitalization rates (OR 0.35). This safety profile differential justifies clinical preference, particularly as payers increasingly track complication costs. Third, AI and imaging integration are reducing the skill barrier: second-generation platforms that embed advanced fluoroscopy or C-arm tomography eliminate the need for additional CBCT capital and shorten procedure cycles, making the economics viable at community hospitals without large volumes. Fourth, the APC complexity adjustment—using bundled codes in an endoscopy suite rather than an OR—converts what had been a marginal or break-even procedure into a profitable service line. Against these drivers, the constraints are substantial. The CPT 31627 facility rate of $85 in 2026 is structurally inadequate relative to capital cost, creating a reimbursement gap that requires high procedure volume or creative coding strategies to close. Capital expenditure of $1–2 million per platform plus $150,000–$300,000 annually in maintenance and disposables creates a payback period that stretches three to five years at moderate volumes. The interventional pulmonology fellowship pipeline is limited: ACGME-accredited training programs produce only a modest cohort of board-certified interventional pulmonologists each year, creating a workforce bottleneck for expansion beyond major centers. Finally, the LDCT screening uptake gap—18% coverage of eligible adults— means the demand funnel feeding into biopsy is operating far below theoretical capacity. Improving screening adherence and follow-up pathways is a necessary market infrastructure investment that individual device companies cannot control but whose pace will significantly determine the size of the accessible market over the next five years.[CM033, CM034, CM035, CM036, CM037, CM038]

2.6 Sizing Uncertainties and Evidence Gaps

The most material evidence gap in this chapter is the ten-fold spread in robotic bronchoscopy market sizing estimates—from $77 million to $640 million for the same nominal segment in 2025–2026. This is not primarily a forecasting disagreement but a scope definition disagreement: narrowly-scoped reports counting only robotic platform hardware revenue arrive at figures one order of magnitude smaller than broadly-scoped reports that bundle navigation software, EBUS accessories, and consumables. No report provides downloadable methodology that would allow independent reconciliation. As a result, any market sizing citation in this chapter should be treated as directionally indicative rather than authoritative, and investors should seek primary channel checks with hospital procurement data to construct bottom-up estimates. A second gap is the absence of publicly available data on the installed base of robotic bronchoscopy systems in the United States. Intuitive Surgical (Ion) and Johnson and Johnson (Monarch) disclose only aggregate procedure counts, and Noah Medical's Galaxy System count is similarly opaque after surpassing the 500-case milestone. Without an installed base figure, a precise SOM calculation for any individual platform is impossible. A third gap is commercial payer policy heterogeneity: while Medicare reimbursement under CPT 31627 and APC 5153 is now codified and publicly available, commercial insurer prior-authorization requirements and coverage policies for robotic navigation bronchoscopy are highly variable and not systematically published, creating unpredictable revenue visibility for hospital bronchoscopy programs. These gaps are not fatal to the investment thesis—the disease burden data and clinical evidence are robust—but they preclude precise SOM sizing and therefore limit confidence in near-term revenue projections for any single-platform competitor in this space.[CM041, CM042, CM043]

2.7 Exhibits

3.1 Competitive Landscape Overview

Robotic-assisted bronchoscopy (RAB) entered commercial use in 2018 and has since consolidated around three FDA-cleared platforms: Intuitive Surgical's Ion (cleared February 2019), Johnson & Johnson's Monarch (cleared March 2018, the earliest entrant), and Noah Medical's Galaxy System (cleared March 2023). Together they address the same clinical problem—accurate tissue sampling of peripheral pulmonary lesions (PPLs)—but via distinct navigation philosophies: shape-sensing fiber optics (Ion), electromagnetic navigation with a robotized scope-in-sheath (Monarch), and electromagnetic navigation with embedded fluoroscopic tomosynthesis (Galaxy). All three platforms are positioned for the bronchoscopy suite and compete head-to-head for capital budgets at academic medical centers and high-volume community hospitals. Beyond the three robotic platforms, Noah Medical also contends with non-robotic navigation solutions: Medtronic's ILLUMISITE fluoroscopic navigation platform, Olympus's EBUS bronchoscope family (including the BF-UCP190F launched September 2025), and institutional CBCT-guided workflows powered by Siemens Cios Spin or GE OEC 3D C-arms. CT-guided transthoracic needle biopsy (TTNB) remains a widely available status-quo substitute with a mature evidence base but substantially higher pneumothorax rates. The competitive set therefore spans high-capital robotic platforms, mid-tier navigation systems, and established procedural substitutes, requiring Noah Medical to establish clinical and economic differentiation across all three categories. Market growth is rapid but the installed base of any individual platform remains small relative to the broader bronchoscopy equipment market, which means every new capital placement is contested and first-mover advantages at a given institution create meaningful multi-year switching barriers. [CP001, CP002, CP003, CP005, CP006]

3.2 Intuitive Surgical Ion — Primary Incumbent and Scale Leader

Intuitive Surgical's Ion is the market-share leader in robotic bronchoscopy by installed base, with 1,041 systems globally as of Q1 2026 (up 22% YoY). Ion procedure volume grew 39% YoY in Q1 2026 to approximately 43,000 procedures, making it the fastest-growing segment within Intuitive's portfolio in that quarter. Mayo Clinic data cited on the Q1 2026 earnings call showed a 79% diagnostic yield and 85% sensitivity for malignancy, bolstering Intuitive's clinical narrative in hospital procurement discussions. Ion's core technical differentiator is its proprietary shape-sensing fiber, which provides continuous real-time location feedback along the full catheter length without electromagnetic navigation and thus avoids the interference issues and registration errors that affect EMN-based systems like Monarch and Galaxy. The system uses a 3.5mm OD articulating catheter with a 1.8mm removable vision probe; the probe must be withdrawn before biopsy tools are inserted, precluding direct visualization at the sampling moment. Confirmation imaging (radial EBUS, fluoroscopy, or CBCT via Siemens NaviLink 3D or GE OEC integration) is therefore operationally important for Ion-based programs. Intuitive's competitive moat extends well beyond the bronchoscopy catheter: Ion benefits from the da Vinci brand's established hospital relationships, ISRG's training infrastructure and service network covering over 11,000 da Vinci systems globally, and the My Intuitive+ digital platform that creates cross-platform data integration. Rapid On-Site Evaluation (ROSE) for cytology adequacy is under development for Ion, which would address one remaining workflow gap. Ion's pricing (~$1.0–1.1M capital plus proprietary instruments) and ISRG's service contracts create high switching costs for any installed customer. [CP002, CP004, CP007, CP008, CP009, CP010]

3.3 J&J / Auris Monarch — First-Mover with Digital Ecosystem Investment

Johnson & Johnson acquired Auris Health for $3.4 billion in 2019 and has since invested in evolving the Monarch platform from its initial electromagnetic navigation architecture toward an AI-powered, imaging-integrated system. Monarch was the first robotically assisted bronchoscopy platform to receive FDA clearance (March 2018) and retains a meaningful installed base built during the years before Ion's commercial launch. The most significant recent development is MONARCH QUEST, which received FDA 510(k) clearance on March 12, 2025. QUEST integrates an NVIDIA RTX-powered AI navigation stack that increases onboard computational power by 260% versus the prior generation, adds intraprocedural 3D imaging data via a verified interface with the GE HealthCare OEC 3D mobile CBCT system, and expands digital capabilities from preoperative planning through postoperative case analytics. QUEST also positions Monarch as a home for future AI software releases within J&J's Polyphonic digital surgery ecosystem, which connects surgical technology, robotics, and software across J&J's broader portfolio—a platform strategy that could differentiate Monarch in enterprise hospital systems already committed to J&J's surgical product lines. Clinical outcome data is a material Monarch headwind: a 2025 propensity score-matched single-center retrospective study (n=365) found Ion's diagnostic yield was 84.2% versus Monarch's 71.0% (p=0.003), with Ion also showing shorter procedure time (37 vs 70 minutes median, p<0.001), shorter radiation time, and lower radiation dose. The pneumothorax rate was numerically lower with Ion (1.0% vs 4.3%), though not statistically significant (p=0.089). No randomized controlled trial has yet directly compared the two platforms, and the study's retrospective single-center design limits generalizability. J&J's investment in QUEST and its CBCT partnership may narrow the performance gap in prospective data. [CP014, CP015, CP016, CP017, CP018, CP019]

3.4 Adjacent Solutions and Non-Robotic Substitutes

Medtronic's ILLUMISITE fluoroscopic navigation platform represents the most clinically validated non-robotic alternative. ILLUMISITE uses digital tomosynthesis to correct CT-to-body divergence in real time and provides continuous navigation guidance throughout the biopsy sequence. The pivotal VERITAS randomized controlled trial—the only RCT in this space—showed ILLUMISITE achieving 79.0% diagnostic accuracy through 12 months versus 73.6% for CT-guided transthoracic needle biopsy, with 6x fewer patient complications (5.0% vs 29.2%). A single-center retrospective study of 72 nodules reported an 87% diagnostic yield. ILLUMISITE's capital cost is lower than robotic platforms (~$500K versus $1.0–1.1M) and it does not require robotic capital approval processes, making it accessible in institutions that have deferred robot procurement. Olympus competes through its EBUS bronchoscope portfolio, most recently the BF-UCP190F launched across EMEA and Asia-Pacific in September 2025. With a 5.9mm OD (versus prior-generation 6mm+ scopes), a 170-degree upward angulation, and 14-degree forward oblique view, the BF-UCP190F extends EBUS-TBNA reach into segmental and sub-segmental airways previously inaccessible to convex-probe EBUS. Olympus holds a very large global installed base of bronchoscopy equipment and benefits from deep relationships with pulmonology departments, particularly for mediastinal staging. Olympus's peripheral bronchoscopy solutions (guide sheaths, rEBUS) complement robotic navigation rather than directly replacing it, but the new slim EBUS scope narrows the gap for peripheral lesions. CBCT-guided bronchoscopy programs using institutional C-arms (Siemens Cios Spin, GE OEC 3D) function as high-performance infrastructure substitutes that some centers deploy instead of or alongside robotic platforms. CBCT adds $400–700K in mobile C-arm capital on top of a navigation platform but provides volumetric real-time 3D tool-in-lesion confirmation; Siemens and GE both market dedicated workflows for integration with Ion (NaviLink 3D). Standalone CBCT bronchoscopy has been shown cost-effective versus CT-guided TTNB in European economic models. An ERS 2025 clinical trial (University Hospital Zurich, n=78 patients, 127 nodules) demonstrated robot-assisted bronchoscopy reached 84% of peripheral tumors versus 23% for traditional bronchoscopy, but also noted that the robotic system costs >$1.1M and adds ~$2,350 per procedure—an explicit cost-effectiveness caution from independent clinical researchers. [CP021, CP022, CP023, CP024, CP025, CP026]

3.5 Capability and Clinical Performance Comparison

The three robotic platforms share the same fundamental clinical goal—accurate peripheral pulmonary nodule biopsy—but diverge on navigation technology, intraprocedural imaging architecture, and scope design. Galaxy's primary technical differentiator is embedded imaging: TiLT+ (digital tomosynthesis combined with augmented fluoroscopy) provides real-time 3D targeting confirmation using standard fluoroscopy equipment already present in bronchoscopy suites, achieving 96.7% concordance with dedicated CBCT in the MATCH 2 prospective multi-center study (n=31). This contrasts with Ion, which requires adjunctive CBCT (or other confirmation modalities) for equivalent targeting confidence because the vision probe is removed at the biopsy step. Galaxy also deploys a single-use disposable bronchoscope in each case, eliminating reprocessing time and cross-contamination risk relative to Ion's reusable catheter and Monarch's reusable scope-in-sheath. In community hospital practice, Galaxy reported an 89% strict diagnostic yield across 70 consecutive cases—a result with practical relevance for centers that cannot justify CBCT infrastructure investment. Ion's shape-sensing fiber avoids electromagnetic interference and registration errors that affect both Galaxy and Monarch, which rely on EMN-based navigation. In the 2025 matched study, Ion's shorter procedure time (37 vs 70 minutes with Monarch) and lower radiation dose are operationally meaningful at high-volume centers. Cleveland Clinic physicians have noted that platform choice depends more on institutional imaging access and workflow than on fundamental navigation capability, as all three systems can successfully navigate to PPLs when used by experienced operators with appropriate adjunctive imaging. Unsupported comparison cells: head-to-head Galaxy vs Ion data from a multi-center RCT is not yet available; cost per procedure for Galaxy beyond the BCM-reported robotic bronchoscopy average is not publicly disclosed; Monarch QUEST imaging outcomes in a prospective trial are pending. [CP028, CP029, CP030, CP031, CP032, CP033]

3.6 Commercial Dynamics, Switching Costs, and Moat Durability

Hospital switching costs in robotic bronchoscopy are high and structurally favor incumbents. Robotic bronchoscopy systems require proprietary instruments and disposables, 5–10 year service contracts, extensive staff credentialing, and procedural room reconfiguration. A hospital that has trained its interventional pulmonology team on one platform faces retraining costs, credentialing timelines, and stranded inventory if it moves to a competitor. Intuitive Surgical compounds this with cross-platform dependencies: Ion customers who also operate da Vinci systems benefit from consolidated training programs and service relationships, increasing the integration penalty for switching any single platform. Intuitive's scale advantage manifests in procedure economics and data assets. Ion's 39% Q1 2026 procedure growth trajectory is generating outcomes data, operator experience, and service-revenue density that smaller-installed-base competitors cannot match near-term. J&J's Polyphonic ecosystem investment positions Monarch as an enterprise platform within hospital systems that standardize on J&J surgical technologies across multiple specialties—a distribution advantage that is difficult for a pure-play bronchoscopy company like Noah Medical to replicate. The most significant structural constraint on all platforms is reimbursement: robotic bronchoscopy is reimbursed under the same CPT codes as conventional navigational bronchoscopy (CPT 31627), with no incremental premium for robotic guidance. This caps hospital revenue per procedure regardless of platform cost and places the economic justification on secondary benefits (reduced repeat biopsies, downstream oncology revenue, patient throughput). A 2024 Baylor College of Medicine analysis found that robotic surgery programs typically face lower insurance reimbursement per procedure despite significantly higher platform and procedure costs, and that programs require at least 120 procedures/year for financial sustainability—a volume threshold that excludes most community hospitals in the near term. This adverse economic reality constrains all RAB competitors equally but disproportionately affects newer entrants seeking to displace established programs with existing amortized capital. Noah Medical's single-use scope strategy lowers sterilization overhead but raises per-case disposable cost, creating a different cost structure from Ion. The commercial implication is that Galaxy's total cost of ownership relative to Ion and Monarch remains a key diligence ask for hospital procurement teams. [CP034, CP035, CP036, CP037, CP038, CP039]

3.7 Exhibits

4.1 Revenue Model and Pricing Architecture

Noah Medical's business model follows the medtech razor-and-blades pattern: hospitals purchase the Galaxy System capital platform, then purchase a single-use disposable bronchoscope for every procedure. The company has explicitly described itself as selling a capital system plus single-use disposables for peripheral lung-nodule biopsy. This architecture creates two distinct revenue streams: an upfront capital sale and a recurring disposable revenue stream that scales with installed base and procedure utilization. A third stream—service and maintenance contracts—is standard in robotic medtech but has not been separately disclosed by Noah Medical. There is also a potential accessories line for procedure components (guide sheaths, needles, and other single-use tools used alongside the bronchoscope), though the company has not described a distinct accessories SKU. Noah Medical has not publicly disclosed the list price of the Galaxy System, the price of the single-use bronchoscope, or any realized pricing data. Competitive context provides useful benchmarks: Intuitive Surgical's Ion endoluminal system is reported in procurement sources at roughly $600,000–$750,000 per system, and Intuitive's overall instruments and accessories segment generated approximately $6.02 billion in 2025 on 3.15 million da Vinci procedures—a recurring-revenue ratio that illustrates the financial leverage of the model at scale. A Johns Hopkins University prospective observational study published in Respiration (2026) measured single-use flexible bronchoscope cost at $300–$400 per unit, while reusable bronchoscope per-use cost ran $198–$202 in the same unit; robotic-compatible proprietary disposables would logically price at or above the commodity disposable range. The Beyond the Scope community-hospital study presented at CHEST 2025 reported cost-benefit ratios of 1.5 (endoscopy suite) and 1.1 (operating room), indicating financial viability at current procedure volumes even in non-academic sites, but does not disclose the company's revenue or margin on those procedures. [CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Funding History and Capital Structure

Noah Medical's most firmly documented financing milestone is its oversubscribed $150 million Series B, closed April 19, 2023, and led by SoftBank Vision Fund with Prosperity7 Ventures (affiliated with Saudi Aramco) as co-lead. The syndicate also included Tiger Global, Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, AME Cloud Ventures, and undisclosed strategic investors, as corroborated by the company's own press release and independent deal coverage. The stated purpose of the Series B was to meet rising demand for the Galaxy System and accelerate R&D for non-invasive platforms for patient diagnosis and treatment. Beyond the Series B, pre-B round history—implying seed and Series A funding that enabled the company's founding in approximately 2018 through FDA clearance in March 2023—is not publicly detailed by Noah Medical. Third-party private-company databases (PitchBook via Premier Alternatives) report an additional $230 million Later Stage VC round in September 2025 that would bring total disclosed capital raised to approximately $516.8 million and post-money valuation to approximately $2.0 billion, reflecting a capital efficiency ratio of ~3.87x (valuation divided by total funding). Noah Medical has made no press release or official statement confirming this later round, and the absence of official confirmation means these figures should be treated as reported but unconfirmed. As a private company, Noah Medical has not disclosed its cap table, liquidation preference stack, board composition, investor pro-rata rights, or anti-dilution provisions—all of which are essential inputs for underwriting valuation and downside scenarios. The company does not hold a public securities filing obligation, so structural disclosure depends entirely on direct management or investor engagement in a formal data-room process. The funding chronology established in the Company Overview (Chapter 1) provides the primary narrative anchor; this chapter mints its own claims for financial use without copying earlier claim IDs. [CI010, CI011, CI012, CI013, CI014, CI015]

4.3 Unit Economics: What Is Known and What Is Not

Noah Medical's unit economics are almost entirely opaque at the public level. No system ASP, disposable ASP, gross margin (capital or disposable), customer acquisition cost, payback period, or revenue per installed system has been disclosed by the company. The available evidence permits only informed inference and peer-benchmarking. On the capital equipment side, the Galaxy System's single-use bronchoscope architecture, compact footprint, and positioning as a cost-effective alternative to incumbent platforms suggest an intended system price below the Ion's reported $600,000–$750,000, though no list price is confirmed. On the disposable side, the Johns Hopkins / Respiration (2026) study and an earlier systematic meta-analysis (Solis-Pazmino et al., Respiration 2022) together show that single-use bronchoscopes price between $150 and $400 per unit in the broader market; proprietary robotic-platform disposables typically command a premium. The margin structure on disposables in analogous medtech systems is high: Intuitive Surgical's instruments and accessories segment ran approximately 65–75% gross margin company-wide in recent years, a useful benchmark for fully scaled proprietary disposable businesses. The hospital-facing procedure economics were partially illuminated by the CHEST 2025 Beyond the Scope study, which reported a cost-benefit ratio above 1.0 in both endoscopy suite and OR settings, demonstrating that the Galaxy procedure can generate a positive economic return for the adopting institution—a precondition for sustained utilization and reorder. However, a positive hospital CBR does not directly translate into Noah Medical's unit economics, which depend on system pricing, disposable pricing, COGS (manufacturing cost per system and per bronchoscope), and the service cost per installed unit. A Getlatka third-party database entry claims $139.3M in ARR for 2025 with a $417.9M valuation, but the same source incorrectly lists a different person as CEO and states $0 raised—making its revenue and valuation figures unreliable and unusable for underwriting purposes. Revenue and unit economics must be obtained directly from the company through a formal diligence process. [CI017, CI018, CI019, CI020, CI021, CI022]

4.4 Capital Intensity, Manufacturing, and Commercialization Costs

Noah Medical operates in one of medtech's most capital-intensive categories: robotic platforms that integrate precision electromechanical hardware, proprietary imaging algorithms, and single-use consumables manufactured under strict quality and sterilization requirements. Industry data for Class II medical device development (the Galaxy System's regulatory class) places total development-to-market costs at $2M–$30M, with manufacturing scale-up consuming an estimated 15–25% of total development budget and commercialization (sales force, KOL programs, training, clinical support) consuming a further 10–20%. For robotic bronchoscopy platforms—which require specialized capital manufacturing infrastructure, direct-to-physician sales and training, field clinical support at each installation, and ongoing clinical evidence generation—these cost categories are likely at the upper end of the range. Intuitive Surgical's Ion placed 195 systems in 2025 and grew Ion procedures 51% year-over-year, but also represented roughly $1.3B in R&D and significant service infrastructure at the parent-company level. The global medtech VC environment reinforced capital concentration: Q1 2025 saw $3.7 billion deployed across 117 deals, with capital concentrated in 13 rounds exceeding $100 million and investors explicitly favoring companies with commercial traction, clinical validation, and clear regulatory pathways—exactly the profile Noah Medical has been building. Nevertheless, 2024 medtech late-stage funding data showed two-thirds of Series C and later rounds securing flat or down valuations, signaling that late-stage capital is harder and more dilutive even for well-positioned companies. For a company at Noah Medical's stage—commercially launched, past 5,000 cumulative procedures, with active clinical evidence generation and expanding field infrastructure—a monthly cash burn estimate of $5–10M is directionally consistent with its disclosed headcount (~300+ employees by late 2025 per third-party estimates) and the operational requirements of robotic medtech, though this is an industry-informed estimate rather than disclosed data. At $5–10M per month, the $150M Series B provided approximately 15–30 months of runway from April 2023 through mid-to-late 2025, which is temporally consistent with the reported September 2025 later-stage round. [CI025, CI026, CI027, CI028, CI029, CI030]

4.5 Reimbursement Dynamics and Procedure Economics

The commercial viability of the Galaxy System depends not only on Noah Medical's pricing and margin structure, but on the hospital's ability to bill and collect for robotic-assisted bronchoscopy procedures. Under current Medicare OPPS, bronchoscopy with biopsy (CPT 31625) carries a hospital outpatient facility payment of approximately $1,724 (national average, 2025 rates), while physician payment under the Medicare Physician Fee Schedule runs approximately $334. These rates apply to the procedure itself regardless of whether a conventional or robotic platform is used, meaning the hospital must absorb the cost of the Galaxy System and its single-use disposable within this reimbursement envelope. At $300–$400 per disposable bronchoscope (per the Johns Hopkins 2026 study benchmark), hospitals must generate sufficient procedure volume and margin from the broader lung-cancer-diagnosis workflow to justify the Galaxy capital investment and per-procedure consumable cost. The CHEST 2025 Beyond the Scope study's reported CBR of 1.5 in the endoscopy suite specifically addresses this question, suggesting the Galaxy procedure generates positive net value for community hospitals even at current Medicare-level reimbursements. However, the CMS regulatory environment introduces material risk: FDA clearance does not guarantee CMS coverage. CMS repealed its MCIT program in 2021 and introduced the Transitional Coverage for Emerging Technologies (TCET) pathway in June 2023; the gap between device authorization and payer coverage can materially delay volume ramp. The RQM+ analysis of medtech reimbursement dynamics explicitly notes that FDA approval does not equal reimbursement, and that generating the real-world evidence CMS requires takes years. Hospital capital-budget constraints are a separate but related barrier: robotic-surgery adoption requires not just positive procedure economics but capital committee approval against competing hospital priorities, and health system capital budgets remain tight post-pandemic. CMS TCET finalization in August 2024 provides a partial on-ramp for breakthrough devices, but coverage timelines remain uncertain for any platform seeking incremental payment recognition. [CI032, CI033, CI034, CI035, CI036, CI037]

4.6 Financial Disclosure Gaps and Evidence Limitations

Noah Medical's status as a private company means that the standard financial metrics required to underwrite an investment are almost entirely unavailable through public sources. The following metrics are explicitly undisclosed as of the run date: revenue (any period), annual recurring revenue or ARR, gross margin (system or disposable), EBITDA or net income, cash on hand, monthly burn rate, runway, customer count, installed base by site, average procedure utilization per installed system, COGS per unit (capital or disposable), customer acquisition cost, sales cycle length, reorder rates, and the preference stack and liquidation waterfall on existing equity. Valuation is also not confirmed by the company: the post-Series-B valuation is entirely undisclosed, and the third-party-reported $2.0B post-money figure (premieralts.com / PitchBook) is consistent with the reported $230M round but has not been officially confirmed. Additionally, the third-party Getlatka revenue estimate ($139.3M ARR) must be disregarded as unreliable given demonstrated factual errors in the same record. Conflicting third-party valuations ($417.9M from Getlatka vs. ~$2.0B from Premier Alternatives) illustrate the data quality problem for private-company financial analysis: neither figure can be relied upon without direct company confirmation. The inability to verify total capital raised (the $230M round is unconfirmed), burn rate, runway, or margin means that capital adequacy—a central diligence question for a growth-stage medtech company that will need continued investment in manufacturing, commercial expansion, and R&D—cannot be assessed from public information alone. These are not unusual gaps for a Series B/late-stage private medtech, but they are complete gaps rather than thin disclosures, and they collectively represent the primary blocker to forming a founded financial opinion without direct company engagement. [CI038, CI039, CI040, CI041, CI042]

4.7 Financial Verdict: Revenue Quality, Margin Path, and Diligence Blockers

Noah Medical's financial profile presents a compelling capital formation story anchored by a confirmed $150M SoftBank-led round, plausible evidence of a later capital infusion that would bring total raised to ~$516M, and a revenue model (capital + recurring disposables) that—if implemented with Ion-level economics as a comparator—could support attractive gross margins on disposables at scale. The 5,000+ procedure milestone reached by March 2025, the CHEST 2025 evidence of positive procedure economics in community hospitals, and the Intuitive Ion's 51% procedure growth in FY2025 all suggest that the robotic bronchoscopy market is real and growing. However, Noah Medical's revenue quality, margin trajectory, and capital adequacy cannot be assessed from public information. The delta between a theoretical high-margin disposables business (if volume scales) and the current cash burn from a sub-scale manufacturing ramp, multi-site clinical support, and national commercial expansion represents the core financial underwriting gap. The reimbursement environment introduces additional optionality risk: procedure economics are positive in current Medicare fee-for-service settings, but any payer-driven coverage restriction or capital-budget freeze would slow placement and utilization growth. A formal diligence engagement must prioritize: (1) audited or management-prepared revenue and gross margin statements by segment (capital vs. disposable vs. service); (2) full funding chronology including pre-B rounds and any 2025 financing; (3) monthly burn rate and projected runway; (4) cap table, preference stack, and board composition; (5) customer contract terms including pricing and reorder commitments; and (6) manufacturing COGS and quality-system audit readiness. Without these, a financially founded investment decision cannot be made. [CI043, CI044, CI045, CI046]

4.8 Exhibits

5.1 Galaxy System Architecture, Components, and Technical Specifications

The Galaxy System is an all-in-one integrated robotic bronchoscopy platform delivered on a single mobile cart. The core architecture integrates four interdependent subsystems: (1) a robotic arm that mounts, articulates, and controls the bronchoscope; (2) a single-use, 4.0 mm outer diameter (OD, measured at tip), four-way articulating disposable bronchoscope with an integrated camera, a single LED light, and a 2.1 mm working channel; (3) electromagnetic navigation (EMN) hardware — including an under-table EMN board and field generator — that localizes scope tip position relative to pre-operative CT anatomy; and (4) the TiLT+ imaging stack, which uses a standard C-arm fluoroscopy unit (not proprietary) to perform digital tomosynthesis and augmented fluoroscopy sweeps for real-time tool-in-lesion confirmation. The working channel diameter of 2.1 mm is compatible with off-the-shelf biopsy tools including fine-needle aspiration needles, forceps, cytology brushes, and flexible cryoprobes; no proprietary Galaxy-branded biopsy accessories exist as of run date. The single-use scope design eliminates reprocessing; a Noah Medical field representative assists with setup and troubleshooting during early adoption. Noah Medical's careers page describes a team of 150+ engineers; VP of Engineering John Shen has publicly stated the platform is a mix of off-the-shelf components — including the robotic arm itself — combined with proprietary custom hardware and software where true value is added, principally in TiLT+. The GUDID database record confirms the Galaxy System (model GAL-001, UDI-DI 00850048825048) is in active commercial distribution. The system requires a pre-procedural CT scan with 0.8–1 mm slice thickness and 0–50% overlap uploaded to the navigational software; the EMN board is placed under the patient on an EMN-compatible procedural table for registration and scope localization. [CE001, CE002, CE003, CE004, CE005, CE006]

5.2 TiLT+ Technology: Digital Tomosynthesis, Augmented Fluoroscopy, and Tool-in-Lesion Confirmation

TiLT+ (Tool-in-Lesion Technology) is the primary technical differentiator of the Galaxy System and is described by VP of Engineering John Shen as "the big differentiator." TiLT+ solves the CT-to-body divergence problem — the systematic mismatch between the pre-procedural CT scan anatomy used for navigation planning and the patient's actual intraprocedural anatomy, which shifts due to breathing, positioning, and tissue deformation. Existing electromagnetic navigation systems rely solely on the pre-op CT registration without a mechanism to update the target position in real time; TiLT+ fills this gap. The TiLT+ imaging subsystem works as follows: after the robotic scope navigates to within approximately 2–3 cm of the target lesion using EMN guidance, the operator isocenters a standard C-arm fluoroscopy unit at the lesion site in three planes (AP, 30° RAO, 30° LAO). With the patient held at an inspiratory breath-hold, the C-arm sweeps from 30° LAO to 30° RAO, acquiring a series of 2D X-ray frames from multiple angles over a narrow arc (typically 15–60°, in contrast to a full 360° CT rotation). Noah Medical's proprietary image-processing algorithms — incorporating AI and machine-learning techniques — reconstruct a 3D tomosynthesis image from this 2D stack, localize the lesion in three dimensions, and update the navigation target to match the patient's actual intraprocedural anatomy. A TiLT board — a pattern of metal reference beads placed under the patient — provides spatial reference for 3D reconstruction from 2D imaging. The reconstructed target is then displayed on augmented fluoroscopy as a graphical overlay atop the live C-arm image, showing both the updated lesion position and the biopsy tool tip position in real time. A proprietary StrikePoint feature quantifies the distance between the tool tip and the lesion center, providing a numeric measure of tool-in-lesion confirmation. True Targeting updates the lesion overlay continuously as the operator advances the biopsy tool. The MATCH 2 prospective bicentric study (Respiratory Medicine, March 2026, PMID 41620189) validated TiLT+ imaging against cone-beam CT (CBCT) ground truth in 31 patients: TiLT+ demonstrated tool-in-lesion in 30 of 31 nodules (96.7%), CBCT subsequently confirmed TIL in 29 of those 30 (concordance 96.7%), and strict diagnostic yield was 96.7%. Mean TiLT+ sweep radiation dose was 59.1 mGy. The FRONTIER first-in-human study reported 100% tool-in-lesion confirmation across 19 nodules with strict diagnostic yield 89.5–94.7%. [CE009, CE010, CE011, CE012, CE013, CE014]

5.3 Clinical Workflow, Bronchoscope Design, and Accessory Stack

The Galaxy System procedure workflow proceeds in a defined sequence: pre-procedure CT upload and 3D path planning, patient positioning on an EMN-compatible table, scope docking and registration, EMN-guided navigation to the lesion vicinity (~2 cm), TiLT+ tomosynthesis sweep for real-time lesion localization, augmented fluoroscopy-guided biopsy tool deployment, and tissue sampling. Rapid on-site evaluation (ROSE) by a cytotechnologist is used in some institutions to confirm sample adequacy. Published case series at USC and MATCH 2 used general anesthesia with endotracheal intubation; ventilator settings per a modified VESPA trial approach (TV 8 mL/kg IBW, PEEP 8–12 cmH2O) are used in some centers to reduce atelectasis during TiLT+ sweeps. The single-use bronchoscope has a 4.0 mm OD, 2.1 mm working channel, and four-way articulation. The camera and LED light are integrated into a tip module that remains in place at the time of biopsy, enabling direct visualization throughout the entire procedure including the sampling moment. This always-on visualization is a key workflow differentiator versus Intuitive Ion's design, where the vision probe must be withdrawn before biopsy tools are inserted. Published case series document the following biopsy tools used with the Galaxy System's 2.1 mm working channel: 21-gauge PeriView FLEX transbronchial FNA needle (Olympus), 1.1 mm flexible single-use cryoprobe (ERBECRYO 2, Erbe Elektromedizin), SuperDimension biopsy forceps (Medtronic), and cytology brushes. The 1.1 mm cryoprobe showed the best diagnostic yield in the USC JTD real-world study. Radial EBUS can also be added for independent lesion confirmation. Setup and teardown are designed for bronchoscopy suite respiratory therapists, with Noah Medical field representative support during early adoption. The company provides a library of training resources on its Insights page, including white papers and recorded presentations covering institution onboarding (e.g., "Building a Robotic Lung Biopsy Program," "The Galaxy Experience: First 90 Cases"). [CE018, CE019, CE020, CE021, CE022, CE023]

5.4 Clinical Evidence — FRONTIER, MATCH, MATCH 2, and Real-World Learning Curve

Four peer-reviewed or substantively published datasets characterize Galaxy System clinical performance as of June 2026: FRONTIER (first-in-human, Macquarie University Hospital, Sydney; published Respirology June 2024, doi 10.1111/resp.14778): 18 patients, 19 nodules, mean lesion size 20 mm, mean distance from pleura 11.6 mm. Results: 100% successful navigation, 100% tool-in-lesion confirmation, strict diagnostic yield 89.5%, intermediate yield 94.7%, diagnostic accuracy 94.7%, sensitivity 94.4%, specificity 100%. Two pneumothoraces (one requiring chest drain). Conducted by interventional pulmonologists with limited prior robotic experience, supporting replicability in centers new to robotic bronchoscopy. MATCH (initial study, pre-commercial data): 100% navigation and diagnostic yield, 95% (19/20) TiLT-confirmed TIL, 5% (1/20) tool-touching-lesion, verified by CBCT. MATCH 2 (prospective bicentric, Inova Fairfax and CHI Memorial, November 2024–August 2025; Respiratory Medicine March 2026; NCT06685133): 31 patients, mean lesion size 16.99 mm (±6.2 mm), 13% bronchus sign, 31% pleural-based. Results: 100% procedural success, 97% TIL by TiLT+ (30/31), 96.7% concordance between TiLT+ and CBCT (29/30), 93.5% CBCT-confirmed TIL overall (29/31), 96.7% strict diagnostic yield (20 malignant + 10 specific benign), 3% pneumothorax (1/31). Mean procedure time 46 minutes, mean TiLT+ radiation dose 59.1 mGy. Learning Curve Study (USC Keck Hospital, Feb 2024–Feb 2025; Journal of Thoracic Disease, 2025): Real-world, non-sponsored, academic training program. 91 patients, 94 nodules, median lesion size 2.1 cm. Overall strict diagnostic yield 68%; pneumothorax 13% (all requiring chest tube); one self-limited massive hemoptysis. Yield improved from 61% in first six months to 75% in subsequent six months. Trainee involvement and complex anatomy identified as contributing factors; comparable to TARGET trial Monarch benchmark (61.6%). Cryoprobe showed superior yield. Beyond the Scope (community hospital, 70 consecutive cases, 18 months; CHEST 2025): 89% strict diagnostic yield. Key predictors of yield: localization in ≥2 augmented-fluoroscopy planes (p<0.001) and direct tool adjustments with peripheral visualization (p=0.01). Cost-benefit ratio 1.5 (endoscopy suite) and 1.1 (OR) — both financially viable (>1). [CE025, CE026, CE027, CE028, CE029, CE030]

5.5 FDA Clearance, Post-Market Safety Record, and Device Recall

The Galaxy System received FDA 510(k) clearance (K223144) on March 1, 2023 under device classification 874.4680 (Bronchoscope, Flexible or Rigid), product code EOQ, with a determination of Substantial Equivalence (SESE) as a Class II device with special controls. The application was received October 4, 2022, reviewed as a Traditional 510(k), and was not reviewed by a third party. Per the GUDID database, the Galaxy System (GAL-001, UDI-DI 00850048825048) is MR Safe, labeled for prescription use only, and single-use by design. Post-market safety: The FDA MAUDE database contains reports of adverse events following Galaxy System procedures. A February 2024 event (MDR key 18699853) involved a patient who experienced bilateral pneumothoraces, cardiac arrest, hemorrhage, pneumonia, and septic shock during a Galaxy-assisted bronchoscopy; the investigation concluded the adverse event resulted from use error — the physician dismissed six scope-buckling workflow-inhibitor error messages without performing the IFU-required fluoroscopy verification before continuing scope advancement, resulting in a kinked scope. The patient subsequently died; the attending physician attributed death to septic shock secondary to pneumonia from pre-existing conditions rather than device malfunction. An August 2024 event (MDR key 20730618) reported a post-procedural pneumothorax requiring chest tube, attributed to anatomical factors (airway tortuosity and catheter stability) rather than device malfunction. Class 2 Device Recall (Z-0693-2025): On October 25, 2024, Noah Medical initiated a Class 2 recall (posted December 18, 2024) of 26 Galaxy System units due to a power supply design issue. The recall reason: the uninterruptable power supply may have a defective component capable of causing power supply short circuit or protective circuit breaker trips, resulting in sudden, unrecoverable power loss; if during a procedure, this could require manual scope removal with risk of lung injury or pneumothorax. The FDA determined cause as Device Design. The recall was classified Open as of the December 18, 2024 posting; resolution status as of June 2026 is not publicly confirmed. [CE035, CE036, CE037, CE038, CE039, CE040]

5.6 IP Portfolio, Engineering Architecture, and Developer Signal

Noah Medical holds a growing portfolio of U.S. patents covering Galaxy System technology. Justia patent assignment records (as of June 2026) document the following issued patents: US12193640 (granted January 14, 2025): Robotic bronchoscopy navigation auto-registration method using EM sensor data transformations; co-inventors include founder Jian Zhang. US12350092 (granted July 8, 2025): Triple imaging hybrid probe — combines positional sensor, ultrasound transducer, and camera in a removably coupled multimodal sensing probe for fused imaging, suggesting a future capability beyond the current bronchoscope design. US12285162 (granted April 29, 2025): Robotic endoluminal suturing instrument with toggle-based needle rotation, indicating a therapeutic roadmap beyond diagnostic bronchoscopy. US12035881 (granted July 16, 2024): Tip velocity control for articulating flexible endoscopes. US12611092 (granted April 28, 2026): Configurable endoscope bending section enabling stiffness/flexibility tradeoff adjustment. US12635860 (granted May 26, 2026): Anti-buckling device for surgical systems — directly addressing the scope-buckling failure mode documented in the February 2024 MAUDE adverse event. The engineering architecture combines proprietary and off-the-shelf components. Per VP of Engineering John Shen's published interview, the robotic arm is off-the-shelf; the scope design, robotic control calibration, and TiLT+ algorithm constitute the core proprietary IP. The TiLT+ algorithm uses AI and machine-learning techniques to reconstruct 3D volume from 2D fluoroscopy frames and is under continued development to improve reconstruction quality and speed. Developer signal: Noah Medical's careers page (June 2026) describes 150+ engineers and actively recruits software engineers, algorithm engineers, robotics engineers, clinical engineers, and manufacturing engineers. Active Greenhouse job postings include Sr. Clinical Engineer (Sunnyvale) and manufacturing-focused roles, reflecting commercial-stage scaling. No public GitHub repository or open-source software contribution is documented for Noah Medical — this is typical for closed-architecture regulatory-controlled medical device companies. [CE042, CE043, CE044, CE045, CE046, CE047]

5.7 Technical Constraints, Evidence Limitations, and Diligence Gaps

Several technical constraints and evidence limitations are material to assessing Galaxy System product risk in 2026: Electromagnetic navigation dependency: The Galaxy System uses EMN for pre-biopsy navigation, which is subject to metallic interference and registration errors from EM field distortions in the procedural environment. TiLT+ corrects for anatomy drift post-navigation, but EMN accuracy for initial path-following degrades in high-ferrous environments. Competing shape-sensing systems (Intuitive Ion) avoid this class of error entirely. CT-to-body divergence correction window: TiLT+ corrects anatomy drift only after the scope has been navigated to within 2–3 cm of the target by EMN. If the initial EMN path alignment fails in tortuous airways — for example because the correct segmental airway is not accessible — the operator may not achieve a viable starting position for the TiLT+ sweep, making the technology's key advantage unreachable. Radiation exposure: The TiLT+ sweep delivers a mean dose of 59.1 mGy per MATCH 2. This is lower than a full CBCT acquisition but is incremental above standard fluoroscopy. In high-volume bronchoscopy programs, cumulative staff and patient radiation exposure from TiLT+ requires tracking per institutional radiation safety protocols; the MATCH 2 paper does not disclose staff dosimetry data. Narrow and non-comparative evidence base: All controlled trials explicitly excluded ground-glass nodules (GGOs), which represent a material and growing share of lung cancer screening detections. The MATCH 2 and FRONTIER studies are small single-arm cohorts (n=31 and n=19). No randomized controlled trial comparing Galaxy against Ion or Monarch has been published as of June 2026. The only independent real-world academic study (USC JTD, 2025) showed materially worse outcomes than controlled trials: 68% yield and 13% pneumothorax. C-arm dependency and capital requirement: The Galaxy System requires a standard C-arm fluoroscopy unit for every TiLT+ sweep; this C-arm is not proprietary but must be available in the procedural room. Centers without a mobile C-arm in the bronchoscopy suite face an additional capital or scheduling dependency. Scope buckling user-error risk: The most severe MAUDE event was caused by repeated dismissal of scope-buckling workflow inhibitor warnings without fluoroscopy verification. The system provides clear on-screen warnings and IFU guidance; the incident was attributed to use error, but the failure pathway requires robust operator training to mitigate. The recently granted anti-buckling patent (US12635860, May 2026) signals active engineering mitigation. Power supply recall: The October 2024 Class 2 recall of 26 Galaxy System units for power supply design issues represents a post-market design quality event. The failure mode — unrecoverable power loss during a bronchoscopy procedure requiring manual scope removal — carries pneumothorax risk. Recall resolution as of run date is not publicly confirmed. [CE050, CE051, CE052, CE053, CE054, CE055]

5.8 Exhibits

6.1 Customer Base Segmentation and Buyer, User, Payer Roles

The Galaxy System's end customer is the hospital or health system that purchases the robotic capital unit and consumes single-use disposable bronchoscopes per procedure. Buyers segment into three identifiable tiers. Academic medical centers (AMCs), such as the University of Chicago Medicine and Inova Fairfax Medical Center (Virginia), are first-mover adopters with large interventional pulmonology programs, robust research infrastructure, and Medicare/commercial payer mixes that support capital investment in advanced bronchoscopy. Large community hospitals—exemplified by CHI Memorial in Chattanooga, Tennessee (part of the CommonSpirit Health network) and Long Island Jewish Medical Center in New Hyde Park, New York (a Northwell Health affiliate)—represent the critical second-tier segment where mid-2024 adoption signals a broadening beyond research centers. Smaller and rural community hospitals, represented by WVU Camden Clark Medical Center in West Virginia, where one of only two interventional pulmonologists in the state operates, form the emerging third tier that the "Beyond the Scope" study demonstrated can achieve economic sustainability with Galaxy. The buyer role is held by hospital administration or a physician-executive service-line leader who builds and champions a capital-expenditure business case through the annual or ad hoc capital committee process. The user is the interventional pulmonologist (IP) who performs procedures; Galaxy's compact footprint and single-use bronchoscope allow deployment in an endoscopy suite, not only in an operating room, which broadens the user setting for smaller sites. The payer for Galaxy-enabled procedures is Medicare (approximately 60% of procedure volume in community settings), supplemented by commercial insurance and, to a lesser extent, Medicaid. The champion at most confirmed sites has been a named IP physician-investigator with early access to Noah Medical's clinical programs and, in several cases, a disclosed financial relationship with the company.[CU001, CU004, CU005, CU009, CU010, CU024]

6.2 Named Customer Proof and Clinical Site Evidence

Seven or more named hospital sites have been confirmed as Galaxy System production users through company press releases, hospital newsroom pages, peer-reviewed publications, and conference presentations. The University of Chicago Medicine was the first U.S. commercial site, performing four successful cases on May 18, 2023—all patients discharged same-day—under Dr. Kyle Hogarth. Dr. Hogarth's published conflict-of-interest disclosure notes he has been a paid Noah Medical consultant since 2018 and holds an equity interest, which is material context when weighting his endorsement as independent physician evidence. Ingalls Memorial Hospital in Tinley Park, an affiliate within the UChicago Medicine network, launched Galaxy bronchoscopy in April 2026, illustrating intra-network diffusion. CHI Memorial in Chattanooga performed the 500th U.S. Galaxy procedure in January 2024, was the first Tennessee hospital to adopt the system, and served as a MATCH 2 study site under Dr. Krish Bhadra. Dr. Bhadra was subsequently appointed Noah Medical's Chief Pulmonary Advisor in June 2026, deepening the company–KOL relationship. Long Island Jewish Medical Center (Northwell Health), under Dr. Abhinav Agrawal, performed the milestone 5,000th U.S. procedure in March 2025. Inova Fairfax Medical Center in Virginia, under Dr. Amit Mahajan, co-led the MATCH 2 study and generated independent field data across 165 procedures showing 92–96% diagnostic yield. Prince of Wales Hospital in Hong Kong, under Drs. Calvin Ng and Rainbow Lau, conducted the first Asian use in December 2023 and initiated the first Galaxy clinical trial in Asia. Macquarie University Hospital in Sydney, Australia, hosted the FRONTIER first-in-human trial beginning March 2023 under Dr. Tajalli Saghaie. At AABIP 2024, additional named Galaxy users were identified: Dr. Joseph Cicenia (Cleveland Clinic), Dr. Matthew Federbush (Northwell Health), and Dr. Sean Callahan (Prisma Health).[CU002, CU003, CU004, CU005, CU006, CU007]

6.3 Adoption Trajectory and Procedural Milestone Evidence

Noah Medical's procedure-count milestones provide the clearest public proxy for adoption velocity. The company reached its first commercial U.S. use in May 2023, the 500th U.S. procedure in January 2024 (approximately eight months post-launch), and the 5,000th U.S. procedure in March 2025—a 22-month ramp from first case to five-thousand. The interval from the 500th to the 5,000th procedure spans approximately 14 months, implying an average of roughly 320–370 procedures per month during the commercial scale-up phase. A run-date (June 2026) cumulative procedure count has not been disclosed. Geographic expansion tracks parallel to procedure volume growth. The first-in-human use in Australia (March 2023) preceded U.S. commercialization and established the Macquarie University Hospital as an early clinical evidence generator. The first Asian commercial use at Prince of Wales Hospital (December 2023) initiated a prospective clinical trial in Hong Kong, extending the evidence base internationally. Intra-network diffusion is evidenced by the April 2026 launch at Ingalls Memorial (UChicago Medicine network), and the presence of named users across at least six U.S. states (California, Tennessee, New York, Virginia, West Virginia, North Carolina/South Carolina region via Prisma Health) and two international geographies (Australia, Hong Kong) confirms multi-geography deployment. The procedural growth trajectory is consistent with multi-site adoption but the total installed-base site count remains undisclosed, making it impossible to independently calculate per-site average utilization or distinguish fast-scaling sites from lower-volume deployments. The company's communications shift from procedure milestones to "rapid adoption" language without providing an account count, a common disclosure pattern for pre-IPO medical-device companies managing competitive intelligence.[CU001, CU004, CU005, CU007, CU014, CU017]

6.4 Hospital Procurement Path and Training Adoption Model

Hospital procurement of the Galaxy System capital unit follows the standard hospital capital expenditure process: a physician champion (typically the interventional pulmonologist leading the lung nodule program) develops a service-line business case covering capital cost, expected per-procedure contribution margin, reimbursement economics, and competitive differentiation against first-generation platforms. This business case goes to the hospital capital committee, which may be annual or require a threshold-crossing approval. Contract negotiation, facility preparation for the system's C-arm-compatible bronchoscopy suite, and training then precede first use. Noah Medical's FRONTIER study demonstrated that "the system can be rapidly and successfully deployed after recommended training, even in areas with minimal robotic experience," suggesting a shallow learning curve by design. The AABIP 2024 program featured multiple Galaxy simulation sessions under the theme "Tips and Tricks for Optimizing Yield in Peripheral Bronchoscopy," and Noah Medical hosted interactive simulation and after-hours events to build physician competency at conferences. The company also offers a reimbursement-support resource (reimbursement@noahmed.com) to help hospital billing teams navigate CPT coding. Despite Noah Medical's positioning of rapid adoptability, the broader robotic bronchoscopy literature documents that implementation requires multi-disciplinary coordination across pulmonology, radiology, anesthesiology, and hospital administration, and that general anesthesia access is a structural requirement—one that constrains deployment in settings with limited anesthesia availability. These barriers are documented by third-party clinical commentators, not company sources, and are relevant to modeling expansion beyond well-resourced facilities.[CU005, CU019, CU024, CU028, CU029, CU037]

6.5 Reimbursement Framework and Customer-Site Economics

The reimbursement environment for Galaxy System procedures has materially improved since the 2023 commercial launch. As of January 1, 2024, CMS awarded Transitional Pass-Through (TPT) status under HCPCS code C1601 to qualifying single-use pulmonary bronchoscopes used in select procedures. A third-party legal analysis conducted for Noah Medical concluded that the Galaxy single-use bronchoscope appears to meet the criteria for TPT payment, which provides an incremental hospital-outpatient payment above standard Medicare APC rates. This TPT designation is set to last three years from January 2024, giving customers enhanced reimbursement through at least December 2026. The primary procedure codes are CPT 31628 and 31629 (transbronchial biopsy), which are cited by Noah Medical as billable with C1601. The "Beyond the Scope" community hospital study presented at CHEST 2025 quantified the economics: procedures in the endoscopy suite produced a cost-benefit ratio of 1.5, and in the OR a ratio of 1.1—both above the financially-viable threshold of 1.0 used by the investigator. The MedCity News opinion article by the Beyond the Scope principal investigator (Dr. Mathew, March 2026) elaborated that moving cases from the OR to the endoscopy suite, combined with complexity-adjusted APC billing (CPT 31628 + 31629 + 31653), can "lift cost-benefit analysis, shorten the payback period, and boost contribution margins per case." Dr. Mahajan (Inova Fairfax) additionally stated the Galaxy System is "financially sustainable" by minimizing direct costs through its single-use bronchoscope design. Capital payback timelines depend on procedure volume and the hospital's payer mix. For sites with tight margins—particularly smaller community hospitals—the economics are viable in endoscopy-suite settings but require disciplined volume ramp and billing discipline. The TPT payment mechanism provides an adoption subsidy that expires post-2026, creating a potential headwind for new site economics after the incentive ends.[CU020, CU021, CU022, CU035, CU038, CU039]

6.6 Retention Signals, KOL Relationships, and Expansion Patterns

Noah Medical has not published formal customer retention metrics—no NRR, GRR, churn rate, contract renewal data, or cohort utilization statistics are publicly available. Durability must be inferred from indirect signals. The most compelling retention proxy is that named early adopter sites (University of Chicago, CHI Memorial, Inova Fairfax) have appeared repeatedly across multiple study cohorts, conference presentations, and named-user contexts spanning 2023 through 2026, suggesting continued active use. Ingalls Memorial's April 2026 adoption within the UChicago Medicine network, more than three years after UChicago's first use, implies that the anchor site remained active long enough to influence network diffusion—a meaningful durability signal, even if anecdotal. The KOL engagement model functions as a hybrid between clinical research partnership and customer success. Dr. Bhadra (CHI Memorial) has served as a MATCH 2 investigator, a CommonSpirit Health Lung Council co-chair, and—since June 2026—Noah Medical's Chief Pulmonary Advisor. Dr. Mahajan (Inova Fairfax) has contributed to both the April 2024 field-data whitepaper and the MATCH 2 study, with multiple public endorsements of the system's financial and clinical value. These relationships create institutional stickiness: physician champions with equity or advisory ties are unlikely to switch platforms mid-tenure, and their research publications generate independent evidence that fuels inbound interest from other hospitals. Expansion signals are visible in two patterns: geographic diffusion from anchor AMCs to network affiliates (UChicago → Ingalls Memorial), and conference-driven adoption where AABIP and CHEST presentations by named users bring the Galaxy System to the attention of the broader interventional pulmonology community. Noah Medical's presence at AABIP 2024 with simulation sessions, a symposium, and after-hours events explicitly targets physician decision-makers who would become future institutional champions.[CU002, CU011, CU013, CU023, CU031, CU032]

6.7 Concentration Risk, Undisclosed Installed Base, and Adoption Barriers

The most material customer-chapter gap is that Noah Medical has not disclosed the total number of hospital sites, active installed base, or customer count as of June 2026. Public evidence names at minimum seven distinct clinical sites generating Galaxy procedures, but this is almost certainly an undercount of the true deployment footprint—the 5,000+ U.S. procedures by March 2025 imply a multi-site deployment well beyond the seven publicly confirmed names. However, without a stated site count, customer concentration cannot be independently assessed. If a significant fraction of the 5,000+ cumulative procedures came from a small number of high-volume KOL sites (UChicago, Inova Fairfax, CHI Memorial), the installed base may be shallower than the procedure milestone implies. Adoption barriers documented in independent clinical literature include: (1) high upfront capital costs, identified as a "significant financial burden" for institutions in a published Thorax BMJ clinical commentary; (2) the requirement for general anesthesia access, which limits deployment in nationalized healthcare systems and resource-constrained settings; and (3) the need for multi-disciplinary staff coordination across pulmonology, anesthesiology, and radiology. These are industry- wide constraints, not Galaxy-specific, but they shape the realistic addressable hospital universe. The post-2026 expiry of TPT C1601 payments will remove an incremental economic subsidy, potentially slowing new-site economics. The most prominent adverse data point on customer evidence quality is the conflict- of-interest structure at early adopter sites: Dr. Hogarth (University of Chicago) disclosed a paid consulting relationship and equity interest; Dr. Bhadra (CHI Memorial) transitioned to company advisor in June 2026; Dr. Mahajan (Inova Fairfax) contributed to physician-adjudicated (not peer-reviewed) whitepapers and served as MATCH 2 PI. The clinical data from these sites is real, but the independence signal is weaker than arms-length third-party evaluation. The Frontiers Oncology review article on the evolution of robotic bronchoscopy (March 2025) did not reference Galaxy at all, centering its analysis on Intuitive Surgical's ION—a signal that Galaxy's academic literature footprint is still modest relative to the ION platform.[CU003, CU018, CU023, CU028, CU029, CU030]

6.8 Exhibits

7.1 Regulatory and Device Safety Risks

The Galaxy System has accumulated four distinct FDA Class 2 device recalls since March 2024, an unusually high frequency for a platform with a limited commercial install base estimated below 100 systems. The pattern signals design-quality control challenges at a critical commercialization stage and may attract enhanced FDA post-market surveillance or require 510(k) supplement filings for design corrections. Recall Z-0693-2025 (initiated October 25, 2024; posted December 18, 2024; status Open as of June 2026) covers 26 Galaxy System units (GAL-001) with a power supply defect: the uninterruptable power supply contains a semiconductor component that can cause a non-recoverable short circuit or circuit-breaker trip. If this failure occurs mid-procedure, the bronchoscope must be manually extracted, increasing risk of lung laceration and pneumothorax. The corrective action remains incomplete as of June 2026. Recall Z-0679-2025 (initiated October 25, 2024; posted December 13, 2024; status Open as of June 2026) covers the Galaxy bronchoscope (GALB-001) used with IFU Revision J and all prior versions for the same affected system serial numbers. The failure mode: not all biopsy tools fitting the 2.1 mm working channel will pass through when the scope is in a sharp bend exceeding approximately 100 degrees; forcing the tool risks tissue injury or pneumothorax. This is an inherent geometric constraint of the single-lumen disposable design. Recall Z-1734-2024 (initiated March 9, 2024; posted May 1, 2024) covers 17 wired controller units (GAL-019) whose torque calibration was misaligned, potentially causing unintended robotic scope motion. Controller motion errors are categorically dangerous during airway procedures. Recall Z-0598-2026 (initiated September 12, 2025; posted November 26, 2025) covers the Galaxy System because user manuals were password protected, preventing operator access to safety-critical IFU content. Inaccessible instructions are a primary FDA recall trigger for procedural misuse. The FDA MAUDE database documents a February 2024 adverse event (MDR 18699853) in which a patient died following a Galaxy procedure. The physician dismissed six scope-buckling warning messages without performing the IFU-required fluoroscopy verification before continuing scope advancement; the resulting kinked scope led to bilateral pneumothorax, cardiac arrest, hemorrhage, and septic shock. While the investigation attributed death to pre-existing pneumonia rather than device malfunction, the event illustrates that user-error failures are enabled by inadequate safeguards. A second 2025 MAUDE event (MDR 21200488) recorded a patient stroke two days post-Galaxy procedure; no device malfunction was attributed, but the report documents the adverse outcome timeline. Noah Medical was granted patent US12635860 (May 26, 2026) specifically for an anti-buckling device for surgical systems, directly addressing the scope-buckling failure mode. The Galaxy System received 510(k) clearance K223144 on March 1, 2023 as a Class II bronchoscope with special controls. No de novo, PMA, or Breakthrough Device designation for the Galaxy System has been publicly confirmed, which limits access to the CMS TCET coverage pathway and potentially signals the regulatory strategy is incremental rather than transformative. International clearance: CE Mark for the EU market is not publicly confirmed as of June 2026, restricting the commercial footprint to the US and an Asia pilot. [CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Reimbursement and Coverage Risks

Medicare does not have a unique CPT code for robotic bronchoscopy. Galaxy System procedures are billed under existing conventional bronchoscopy codes: 31628 (transbronchial lung biopsy, single lobe) as the primary code, plus add-on code 31627 (computer-assisted navigational component) when electromagnetic navigation is used. No incremental robotic premium is available, meaning Noah Medical's sophisticated TiLT+ imaging technology generates the same CMS reimbursement as a manually guided procedure. The navigator add-on 31627 reimburses approximately $70–$120 per procedure under the Physician Fee Schedule, offering marginal uplift versus the operational cost of the Galaxy platform. CMS's TCET (Transitional Coverage for Emerging Technologies) pathway, finalized August 2024 and effective 2025, offers expedited national Medicare coverage for FDA-designated Breakthrough Devices that meet strict clinical criteria. The pathway accepts up to five candidates annually. Noah Medical has not publicly indicated that the Galaxy System has been nominated for or accepted into the TCET pathway, and the Galaxy's 510(k) classification as a standard Class II device rather than a Breakthrough Device may preclude eligibility without redesignation. Even if eligible, TCET typically requires Coverage with Evidence Development (CED)—additional data collection after commercialization—which extends the period of coverage uncertainty and clinical-trial burden. CMS implemented a -2.5% efficiency adjustment on many non-time-based physician services in the 2026 Physician Fee Schedule, further compressing per-procedure reimbursement. Simultaneously, the AHA 2025 report documented that Medicare reimbursed hospitals only 83 cents per dollar of care delivered in 2023, and hospital operating margins remained structurally thin going into 2026. These dynamics increase hospital price sensitivity to disposable consumable costs for each Galaxy procedure, potentially lengthening the payback period on capital investment. Commercial insurer coverage for robotic bronchoscopy is inconsistent across payers and geographies; each new account may require prior authorization workflows, clinical documentation requirements, and payer-specific coverage reviews. The RQM+ medtech industry analysis warns explicitly that regulatory approval does not guarantee market success: multiple FDA-cleared devices have faced years of reimbursement non-coverage after clearance. Without a proactive payer coverage strategy—national coverage determination or broad LCD—the Galaxy System's revenue potential is constrained to hospitals where favorable payer mix or institutional cost-center absorbs the disposable. [CR010, CR011, CR012, CR013, CR038, CR039]

7.3 Clinical Evidence Limitations, Adoption Friction, and Training Risks

The Galaxy System's sponsor-funded clinical evidence shows compelling results: 96.7% strict diagnostic yield (MATCH 2, n=31), 100% tool-in-lesion confirmation (FRONTIER, n=19), and 89% yield in community-hospital real-world use (Beyond the Scope, n=70, CHEST 2025). However, the independent, non-sponsored USC Keck Hospital learning curve study (Journal of Thoracic Disease 2025, n=91 patients, 94 nodules) documented a 68% overall strict diagnostic yield and a 13% pneumothorax rate—all requiring chest tube placement. A separate case report documented self-limited massive hemoptysis. This real-world-versus-study divergence is a classic device adoption risk: sponsor-selected centers with experienced operators and optimized protocols outperform community and training environments. The 13% pneumothorax rate is clinically meaningful and raises questions about early-center operator selection and training adequacy. Intuitive Ion real-world data from high-volume centers (Annals of Thoracic Surgery 2025, shape-sensing robotic data) reports diagnostic yield of 91% and effectively zero pneumothorax, establishing a credible comparative benchmark that payers and hospital administrators may use to evaluate Galaxy's real-world performance. A propensity-score matched comparison of Monarch vs. Ion (Annals of Thoracic Surgery 2025) gave Ion 84% yield vs. Monarch's 71%, further illustrating that Galaxy's real-world 68% year-one yield is at the lower end of the established robotic bronchoscopy range. Yield improved to 75% in the USC study's second six months, suggesting a 20–50-case learning curve is required before operators reach confident performance—consistent with industry estimates of 20–50 cases for robotic bronchoscopy proficiency. Interventional pulmonology (IP) is a small, specialized subspecialty. HRSA's 2023-2038 physician workforce projection shows 31 of 35 specialties will face shortfalls by 2037; pulmonology is among the most demand-constrained. IP fellowship training positions do not expand proportional to technology adoption, which means the pool of qualified Galaxy operators grows slowly. Noah Medical addresses training risk with an embedded clinical applications specialist model—field representatives attend early cases—but this model has a unit economics ceiling: each additional install requires sustained field-support headcount, compressing contribution margins and restricting simultaneous rollout velocity. Hospital credentialing committees require documented competency protocols before clearing physicians for independent use, adding administrative burden beyond the manufacturer's training program. The Cleveland Clinic advisory identifies operator experience, tool selection, and multiplanar visualization use as the primary yield determinants, confirming that simply placing a Galaxy System does not guarantee high diagnostic yield without a structured training pathway. [CR014, CR015, CR016, CR017, CR018, CR019]

7.4 Competition, Channel, and Market Position Risks

Intuitive Surgical's Ion platform is the primary competitive threat to Galaxy market share growth. As of Q1 2026, Ion's installed base reached 1,041 systems (22% YoY growth), Q1 2026 Ion procedures grew 39% YoY, and full-year 2025 Ion procedures reached approximately 144,100 (51% growth). Intuitive posted Q1 2026 revenue of $2.77 billion (+23% YoY) and ended Q1 2026 with $7.98 billion in cash and investments—a financial position Noah Medical cannot approach. Intuitive's scale enables sustained investment in clinical evidence generation, sales force deployment, pricing flexibility, and value-based contracting with hospital systems. Each quarter Intuitive places 40–52 new Ion systems; at this pace, the Ion installed base doubles approximately every 3–4 years with an ever-larger recurring disposable revenue base that can fund further R&D and commercial expansion. J&J MedTech's Monarch platform, supported by J&J's full legal, regulatory, and financial resources, represents a second entrenched competitor. J&J filed and prosecuted a multi-year trade secret lawsuit against Noah Medical (2022–2025)—an action that simultaneously pressured Noah's management team, consumed legal resources, and served as a competitive intelligence exercise. The dismissal with prejudice in March 2025 resolved the litigation but does not prevent future IP challenges on different grounds or by different J&J subsidiaries. Medtronic's ILLUMISITE and Olympus robotic platforms add further competition for hospital bronchoscopy suite capital budgets. Galaxy has no published head-to-head randomized trial against Ion or Monarch. All published Galaxy data uses single-arm designs, which are vulnerable to sponsor bias, patient-selection effects, and non-standardized outcomes definitions. Payers evaluating coverage criteria for robotic bronchoscopy generally require head-to-head evidence against the standard of care or an established comparator, and the absence of such data delays broad commercial payer acceptance. The competitive timing risk is material: if Intuitive Ion achieves a dominant position—hospital relationship lock-in, disposables contract bundling, and deep KOL entrenchment—before Galaxy reaches scale, the cost of winning share becomes prohibitive. Galaxy's TiLT+ imaging differentiation is real but not irreplaceable: Intuitive has announced continued Ion platform development, and the competitor platforms are investing in confirmation imaging capabilities (Monarch QUEST, cleared March 2025 with GE OEC 3D integration). [CR020, CR021, CR022, CR023, CR024, CR029]

7.5 Manufacturing, Supply Chain, and Operational Risks

Noah Medical's business model creates two distinct manufacturing dependencies: the Galaxy System capital platform (precision electromechanical, reusable) and the Galaxy bronchoscope disposable (single-use, sterile, per-procedure). Any disruption to either line directly impairs hospital procedural throughput and revenue. The disposable bronchoscope must be produced at scale to sustain an expanding procedure volume—each installed Galaxy System requires a continuous supply of per-procedure consumables, and supply shortfalls translate immediately to deferred or cancelled patient procedures. The recall history (four Class 2 recalls in approximately 26 months) reflects manufacturing quality challenges. ISO 13485 compliance is mandatory, and a sustained pattern of field corrections can trigger FDA quality system inspections or Warning Letters, escalating regulatory burden and cost. The biopsy-tool channel incompatibility documented in Z-0679-2025 reflects a geometric design constraint in the bronchoscope that affects all deployed units rather than a discrete manufacturing defect—suggesting the underlying issue requires a product redesign, not a simple field correction. Hospital capital spending headwinds add demand-side risk: 40% of hospital executives surveyed in 2025-2026 planned to cut or defer capital equipment spending; tariffs on imported medical technology components are expected to increase hospital expenses 15% or more; and CMS's 2026 reimbursement adjustments compressed per-procedure revenues. MPO Magazine's 2026 analysis of capital medical device sales confirms that hospital purchasers have moved to a "selective capex" posture, requiring demonstrated ROI before approving high-ticket robotic platforms. These headwinds do not prevent Galaxy adoption, but they lengthen sales cycles and require more extensive hospital economic modeling and vendor-financing alternatives. Single-use disposables also attract environmental scrutiny. Hospital sustainability commitments increasingly evaluate the waste stream from disposable medical devices; regulatory agencies in Europe have proposed extended producer responsibility for single-use device plastics. This creates a reputational and regulatory risk for Noah Medical's disposable-centric model, particularly as EU expansion requires CE Mark compliance with an increasingly demanding environmental regulatory environment. Supply chain concentration risk is elevated for a startup: Noah Medical presumably relies on a limited number of qualified contract manufacturers and raw material suppliers for microelectronic, optical, and polymer components; no public disclosure of supply chain diversification strategy exists. [CR025, CR026, CR027, CR028, CR036, CR037]

7.6 Legal, IP, and Governance Risks

The settled Auris Health v. Noah Medical trade secret litigation (N.D. Cal. 3:22-cv-08073, December 2022 – March 2025) was the most material legal risk event in Noah Medical's history. Auris Health (J&J subsidiary), Verb Surgical, and Cilag GmbH alleged that multiple former Auris employees—including Noah Medical's founder Dr. Jian Zhang—misappropriated trade secrets related to endoscopic robotics systems when joining Noah Medical. The complaint alleged unauthorized copying of confidential robotics platform files and their use in Noah Medical's patent filings and product development. After surviving a motion to dismiss in November 2023 and advancing through discovery, the case was dismissed with prejudice by stipulated order in March 2025, indicating a confidential settlement. While the resolution is favorable, the dismissal with prejudice does not eliminate all IP risk: J&J or its affiliates could file new claims on different IP grounds, and the settlement terms are undisclosed. More structurally, the litigation confirmed that Noah Medical's engineering team includes former Auris employees with deep robotic endoscopy expertise—an asset that also represents a continuing source of IP challenge risk. Corporate governance is opaque. Noah Medical is a private company with no SEC filings obligation; board composition, investor rights agreements, liquidation preferences, anti-dilution provisions, and management compensation are entirely undisclosed. The absence of governance disclosure means investors cannot assess whether controlling investors (SoftBank Vision Fund, Tiger Global) hold board seats with veto rights over financing, M&A, or key personnel decisions, and whether these rights could be triggered by financial covenants or milestone failures. SoftBank Vision Fund has experienced significant portfolio write-downs and strategic pivots in recent years; any change in SoftBank's investment posture could affect willingness to participate in future rounds or exercise governance rights. Data privacy and HIPAA compliance risks are present given that the Galaxy System processes patient imaging and EM navigation data; no public disclosure of Noah Medical's data security practices, HIPAA compliance architecture, or incident history exists. [CR029, CR030, CR031, CR032, CR041]

7.7 Financing, Runway, and Execution Risks

Noah Medical's confirmed capital raises total $150M (Series B, April 2023, SoftBank Vision Fund-led). A subsequent $230M Later Stage VC round (September 2025) is reported by Premier Alternatives/PitchBook with an implied post-money valuation of approximately $2.0 billion, but this round has not been confirmed by the company in any press release or official communication. Treating only confirmed capital as established, and applying industry-benchmarked burn rates for a commercial-stage robotic medtech with approximately 300 employees—$5–10M per month—the $150M Series B implies approximately 15–30 months of runway from close. This calculus places potential runway exhaustion in the July 2025 – April 2026 window unless revenue is substantial or additional capital was secured. The unconfirmed $230M round, if it closed in September 2025 as reported, would extend runway into late 2027 at the high end—but without confirmation, investors cannot underwrite this assumption. The absence of all financial disclosure—revenue, ARR, gross margin, burn rate, cash balance, and runway—makes independent assessment of Noah Medical's financial health impossible. Latka.com, a low-reliability source, reported $139.3M ARR for Noah Medical in 2025, but the same source has demonstrably incorrect data on the company's leadership and funding history, making the revenue figure unreliable. No credible independent revenue estimate exists. Downstream financing risk is elevated: medtech Series C and later rounds in 2024 saw two-thirds securing flat or down rounds per Nocturnal's 2024 investment data analysis; robotic medtech burn and capital intensity remain high; and a missed revenue ramp or sustained recall activity could impair the company's ability to raise at current valuation multiples. Noah Medical is a single-product company. All revenue, operational capability, and enterprise value depend on the Galaxy System. A major adverse regulatory event—recall escalation to Class 1, Warning Letter, market withdrawal order, or 510(k) hold—would simultaneously eliminate revenue, impair customer confidence, and deplete management bandwidth. Key-person dependency on Dr. Jian Zhang (CEO and co-founder) and a small senior team creates continuity risk; the Auris litigation established that these individuals carry litigation history that could resurface. Geographic single-market dependency on the United States amplifies concentration risk; CE Mark clearance is unconfirmed, and EU MDR compliance pathways are substantially more demanding than FDA 510(k), requiring clinical evaluations against the MDR Annex XIV/XV standards and involving Notified Body review timelines that can extend 18–36 months from filing. [CR033, CR034, CR035, CR036, CR040, CR041]

7.8 Exhibits

8.1 Disclosed Valuation and Funding Evidence

The most firmly documented financing event for Noah Medical is its $150 million Series B, announced April 19, 2023, led by SoftBank Vision Fund and Prosperity7 Ventures (Aramco affiliate), with a broad syndicate including Tiger Global, Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, and AME Cloud Ventures. This round was announced via company press release and corroborated by multiple independent deal-coverage outlets. It remains the only officially confirmed financing event. Tracxn's public profile of Noah Medical (last updated June 6, 2026) classifies the company as a "soonicorn" and shows a January 2021 early-stage VC round as the visible pre-B financing; total funding history is partially gated. Premier Alternatives, citing PitchBook data, reports a $230 million Later Stage VC round in September 2025 that would bring total capital raised to approximately $516.8M and post-money valuation to $2.0B as of September 24, 2025 — a capital efficiency ratio of 3.87x. Noah Medical has made no official press release or statement confirming this round, and the absence of official confirmation means the $2.0B figure must be treated as reported but unverified. A third source, Latka, reports a deeply conflicting $417.9M valuation with $139.3M ARR; Latka's methodology for private companies is opaque and reliability is low. These three data points—$150M confirmed Series B, $2.0B unconfirmed (Premier/PitchBook), and $417.9M conflicting (Latka)—constitute the full universe of publicly available valuation evidence as of June 2026. [CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Funding-Based Valuation Heuristics

In the absence of confirmed revenue, analysts commonly apply funding-based heuristics to frame private company valuations. For Noah Medical, the 3.87x capital efficiency ratio (reported $2.0B valuation / $516.8M raised) is a useful starting point, though it conflates post-money accounting with economic value. Private medical robotics companies at the Later Stage VC level typically exhibit capital efficiency ratios between 2x and 6x depending on technology maturity, installed base, and investor confidence — Noah Medical's 3.87x sits comfortably within this range. However, capital efficiency ratios measure neither profitability nor growth rate; they describe only the relationship between funding and the valuation set at the last round. Tracxn's funding data identifies an early-stage VC round in January 2021 (reported by third parties as approximately $137M), prior to the April 2023 Series B. If the reported September 2025 $230M round is genuine, the step-up in valuation between the April 2023 Series B and the 2025 round implies meaningful upward re-pricing consistent with demonstrated commercial progress (5,000 procedures by March 2025, Galaxy 2.0 launch, CHEST 2025 data). The capital efficiency ratio does not imply intrinsic fair value; it is better understood as a market-clearing price set by institutional investors with information advantages over public observers. Revenue multiples cannot be calculated without confirmed revenue figures; the analyst therefore declines to apply revenue multiples and instead relies on comparable-set benchmarking and scenario analysis. [CV007, CV008, CV009, CV010, CV011, CV041]

8.3 Public Comparable Set and Market Multiples

The closest publicly traded comparable company is Intuitive Surgical (ISRG), which operates the Ion robotic bronchoscopy platform directly competing with the Galaxy System. As of June 23, 2026, ISRG trades with a market cap of approximately $142B, EV/Revenue of approximately 13x (trailing), and a PS ratio of 13.4x on full-year 2025 revenue of approximately $10.07B — the company grew revenue 21% in 2025 and expects 13–15% procedure volume growth in 2026. The Ion platform specifically placed 52 new systems in Q1 2026, bringing its installed base to 1,041 with 39% YoY procedure growth. ISRG's EV/Revenue and PS multiples are appropriate only as a ceiling benchmark for a fully scaled, highly profitable incumbent; private-stage comparisons must apply a meaningful illiquidity and stage discount (typically 30–60% for VC-backed companies versus publicly traded peers). Medtronic, a diversified large-cap medtech with a surgical robotics asset (Hugo, FDA-cleared December 2025 for urologic procedures), trades at approximately 3.3x forward P/S — reflecting the large-cap diversification discount rather than a pure surgical robotics comp. The robotic bronchoscopy market itself was approximately $64.7M globally in 2024, projected to reach $234M by 2031 at a 22% CAGR, suggesting Noah Medical's addressable sub-market is relatively small at current scale. At the broader surgical robotics level, the market grows from $8.28B in 2025 to an estimated $16.4B by 2032 (10.25% CAGR), providing long-term tailwind context. These public comps suggest that a $2.0B valuation for Noah Medical is not inherently unreasonable for a company with demonstrated category leadership, strong clinical proof, and a differentiated platform in a growing market — but it requires revenue in the $150M+ range at ISRG-comparable margins to be technically supportable at public-market multiples. [CV012, CV013, CV014, CV015, CV016, CV021]

8.4 Private Comparable Context and Exit Benchmarks

Among private surgical robotics peers, CMR Surgical is the most directly comparable by stage and capital profile: it raised $200M+ in a round led by Trinity Capital in 2025 (after a $2.7B valuation in its 2021 Series D), has deployed 200+ Versius systems globally, achieved FDA De Novo authorization for cholecystectomy in October 2024, and has raised over $1B in total — positioning it as the best-funded private soft-tissue surgical robotics peer. CMR's $2.7B 2021 mark and subsequent undisclosed 2025 raise illustrate the private mark persistence phenomenon: once a premium valuation is established in a credible round, it tends to persist absent a formal re-pricing event. Distalmotion ($390M total raised, $150M Series G in November 2025) represents a more nascent robotic surgery peer targeting ambulatory surgery centers. At the M&A level, medtech deal value reached $80B in 2025 per Bain's 2026 Global M&A Report — up from $68B in 2024 and $39B in 2023 — with the second half of 2025 particularly strong. Stryker's $4.9B acquisition of Inari Medical illustrates the premium paid for category-specific commercial leaders. The Bain 2026 report specifically notes that "softer valuations will heighten competition for high-quality assets" in 2026, meaning qualified assets like Noah Medical (if revenue and margin profile is confirmed) could attract premium strategic interest in the current environment. Shenzhen Edge Medical raised $154M in a January 2026 HKEX IPO for surgical robotics, indicating ongoing international capital availability for commercialised platforms. The surgical robotics IPO window is cautiously open in 2026 per healthcare.digital analysis, with CMR Surgical actively exploring a potential NASDAQ dual-listing. [CV017, CV018, CV019, CV020, CV044, CV045]

8.5 Strategic Value Drivers and M&A Plausibility

Noah Medical's strategic value rests on four pillars: (1) a proprietary real-time imaging technology (TiLT+) that enables 96.7% diagnostic yield in peripheral lung nodule biopsy without mandatory CBCT infrastructure, directly addressing the community-hospital access gap that Ion and Monarch require adjunctive imaging to bridge; (2) FDA 510(k) clearance (K223144, March 2023) with a documented procedure safety profile; (3) rapid clinical adoption — 10,000+ procedures as of April 2026, 50+ installed systems — providing a growing recurring disposable revenue stream; and (4) strategic investor backing from SoftBank Vision Fund, Prosperity7 (Saudi Aramco), Tiger Global, Hillhouse, and Sequoia China, whose combined imprimatur provides international commercial optionality. The Tier-1 clinical framing — "enabling diagnoses previously infeasible" — that Noah Medical articulated in its April 2026 deep-dive research series is consistent with the investor narrative that commands premium multiples in medtech M&A. As of June 2026, no acquisition or merger rumors involving Noah Medical and any named strategic buyer (Stryker, J&J, Intuitive, Medtronic, Olympus) have been confirmed or credibly reported. However, the strategic logic is clear: J&J already operates Monarch and is executing on the Polyphonic AI ecosystem; Intuitive competes directly via Ion; and Medtronic, Olympus, and Stryker each have bronchoscopy, robotic surgery, or pulmonology adjacencies. Galaxy's community-hospital reach — the one dimension where Ion and Monarch are weakest — creates a genuine acqui-hire and installed-base rationale. The M&A discount for Noah Medical's stage (single-product, concentrated in US bronchoscopy, two open recalls) means any strategic offer would likely price relative to confirmed revenue, not reported valuation. [CV022, CV023, CV024, CV025, CV026, CV027]

8.6 Preference Stack, Dilution, and Disclosure Caveats

Noah Medical has not publicly disclosed its capitalisation table, liquidation preference structure, anti-dilution provisions, investor pro-rata rights, board composition, option pool size, or any debt obligations. These omissions are standard for a private company with no public reporting obligation, but they are material blind spots for any investor attempting to underwrite fair value or downside scenarios. SoftBank Vision Fund rounds historically include participating preferred structures with 1x–2x liquidation preferences; if such terms apply to the Series B, common equity (and later-round preferred) holders face meaningful preference overhang in downside scenarios. The late-stage medtech financing environment in 2024–2025 was challenging: approximately two-thirds of Series C and later rounds priced flat or down per industry data, with investor protections (ratchets, anti-dilution clauses, PIK dividends) becoming more common. Noah Medical appears to have avoided a documented down round between April 2023 and September 2025, but the absence of official confirmation of the $230M round means even this positive signal is unverifiable. The IPO bar for medtech robotics companies in 2026 requires $40–60M run-rate revenue and 60–80% gross margins per healthcare.digital analysis; Noah Medical has disclosed neither figure. Without data-room access, the analyst cannot model a credible enterprise-value waterfall, dilution scenario, or return distribution. All valuation figures in this chapter should therefore be understood as indicative marks rather than underwritten fair values. Material gap: the cap table, preference stack, and any debt instruments are the single highest-priority diligence items before any investment decision. [CV028, CV029, CV030, CV031, CV032, CV033]

8.7 Bull/Base/Bear Scenarios and Investment Recommendation

The bull case assumes Noah Medical achieves category leadership in robotic bronchoscopy — reaching 200+ installed systems and $300–500M in revenue by 2028–2030 — maintains premium margins (60–70% gross margin consistent with capital-plus-consumables robotic medtech), and exits via strategic M&A at 8–12x revenue or via IPO at ISRG-comparable multiples. Under this scenario, enterprise value of $3B–$6B is plausible, representing 1.5x–3x the reported 2025 mark. The base case assumes Galaxy builds to 80–100 systems, generates revenue of $100–$200M, achieves reimbursement stability post-TPT, and is acquired by a strategic buyer or completes a Series C round sustaining the $2.0B mark; dilution-adjusted returns would depend heavily on preference structure. The bear case is anchored to three concurrent risks: TPT reimbursement expiration in late 2026 suppresses hospital purchasing, competitive displacement by J&J Monarch QUEST or ISRG Ion accelerates, and the company's recall history creates regulatory burden. Under bear-case assumptions, a flat or down round at $0.5B–$1.0B, or a distressed strategic sale below the last reported mark, is plausible. The base recommendation is: research more before underwriting. The $2.0B valuation is conditionally supported — within the range of comparables for a well-backed late-stage medtech robotics company at this stage of commercialisation — but cannot be independently verified or discounted without confirmed revenue, margin, burn, preference stack, and cap table. The highest-priority triggers that would change this stance positively are: (1) official confirmation of the September 2025 round with round terms; (2) confirmed revenue ≥$150M at ≥65% gross margin; (3) TPT extension or dedicated CPT code passage. Negative triggers: reimbursement deterioration, a down round or flat round below $2.0B, additional FDA recalls, or clinical data replication failures. [CV034, CV035, CV036, CV037, CV038, CV039]

8.8 Exhibits